OPTHEA LIMITED

INVESTOR PRESENTATION - OPTHEA LIMITED

ASX:OPT

OPTHEA LIMITED

Health Care

Opthea Limited (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around VEGF-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. Opthea’s product development programs are focused on developing OPT-302 for retinal eye diseases including wet Age-related Macular Degeneration and Diabetic Macular Edema (DME). OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF- C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A and has reported outcomes from an international, multi-centre, prospective, sham-controlled, double-masked, superiority study that enrolled 366 treatment-naïve patients with wet AMD. Participants in the study were randomized in a 1:1:1 ratio to receive one of the following treatment regimens administered every 4 weeks for 24 weeks: OPT-302 (0.5 mg) in combination with ranibizumab (Lucentis®) (0.5 mg); OPT-302 (2.0 mg) in combination with ranibizumab (0.5 mg); or sham in combination with ranibizumab (0.5 mg). The study met the primary endpoint demonstrating superior vision gains in participants who received OPT-302 (2.0 mg) in combination with ranibizumab on a monthly basis over 6 months. Opthea is also investigating OPT-302 in a Phase 2a clinical trial in patients with persistent, centre-involved DME. Further details on the Company’s clinical trials can be found at: www.clinicaltrials.gov, Clinical trial identifiers: NCT02543229, NCT03345082 and NCT03397264.

Read more

Market Cap

635.21m

Price at Close

$2.36

4w avg. Volume

554.52k

4w avg. Turnover

$1.35m

Announcements
announcementt+2 movementdate
  • Opthea Key Opinion Leader Symposium Presentation

    Periodic Reports

  • -1.64%

    06 Aug 2020

-1.64%

06 Aug 2020
  • Opthea to Host Key Opinion Leader Symposium on wAMD and DME

    Other

  • -5.34%

    27 Jul 2020

-5.34%

27 Jul 2020
  • Initial Director's Interest Notice - LG

    Shareholder Details

  • -5.34%

    27 Jul 2020

-5.34%

27 Jul 2020
  • Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)

    Periodic Reports · Market sensitive

  • -5.34%

    26 Jul 2020

-5.34%

26 Jul 2020
  • Opthea Presents New Data from Ph 1b/2a DME Trial at ASRS

    Progress Report · Market sensitive

  • -5.34%

    26 Jul 2020

-5.34%

26 Jul 2020
  • Opthea Appoints New Non-Executive Director

    Company Administration

  • -6.99%

    23 Jul 2020

-6.99%

23 Jul 2020
  • Opthea to Present OPT-302 DME Clinical Data at ASRS 2020

    Progress Report

  • +13.91%

    22 Jul 2020

+13.91%

22 Jul 2020
  • Change in substantial holding

    Shareholder Details

  • -4.84%

    26 Jun 2020

-4.84%

26 Jun 2020
  • Change in substantial holding

    Shareholder Details

  • -2.12%

    22 Jun 2020

-2.12%

22 Jun 2020
  • Opthea Added to the S&P/ASX 300 Index

    Other

  • -2.12%

    21 Jun 2020

-2.12%

21 Jun 2020
Market Data

Current Price

$2.36

52WK HIGH

$4.15

52WK LOW

$1.165

1YR RETURN

-9.23%

1YR RETURN VS. SECTOR

-38.03%

90 DAY RETURN

-13.55%

ASX RANK

312

/2,032

SECTOR RANK

5

/47

SHARES OUTSTANDING

269.16m
ASX:OPT

OPTHEA LIMITED

Health Care

Opthea Limited (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around VEGF-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. Opthea’s product development programs are focused on developing OPT-302 for retinal eye diseases including wet Age-related Macular Degeneration and Diabetic Macular Edema (DME). OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF- C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A and has reported outcomes from an international, multi-centre, prospective, sham-controlled, double-masked, superiority study that enrolled 366 treatment-naïve patients with wet AMD. Participants in the study were randomized in a 1:1:1 ratio to receive one of the following treatment regimens administered every 4 weeks for 24 weeks: OPT-302 (0.5 mg) in combination with ranibizumab (Lucentis®) (0.5 mg); OPT-302 (2.0 mg) in combination with ranibizumab (0.5 mg); or sham in combination with ranibizumab (0.5 mg). The study met the primary endpoint demonstrating superior vision gains in participants who received OPT-302 (2.0 mg) in combination with ranibizumab on a monthly basis over 6 months. Opthea is also investigating OPT-302 in a Phase 2a clinical trial in patients with persistent, centre-involved DME. Further details on the Company’s clinical trials can be found at: www.clinicaltrials.gov, Clinical trial identifiers: NCT02543229, NCT03345082 and NCT03397264.

Read more

Market Cap

635.21m

Price at Close

$2.36

4w avg. Volume

554.52k

4w avg. Turnover

$1.35m

ASX:OPT is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

(03) 9028 2888

deals@freshequities.com

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.